Search results for "Vascular endothelial growth factor A"

showing 10 items of 180 documents

Development and Aging Are Oxygen-Dependent and Correlate with VEGF and NOS along Life Span

2012

During development and aging, vascular remodeling represents a critical adaptive response to modifications in oxygen supply to tissues. Hypoxia inducible factor (HIF) has a crucial role and is modulated by oxygen levels, with an age-dependent response in neonates, adult, and aged people. ROS are generated under hypoxic conditions and the accumulation of free radicals during life reduces the ability of tissues to their removal. In this immunohistochemical study we investigated the presence and localization of VEGF and iNOS in human carotid bodies (CB) sampled at autopsy from three children (mean age – 2 years), four adult young subjects (mean age – 44.3 years), and four old subjects (mean ag…

AdultVascular Endothelial Growth Factor AAgingmedicine.medical_specialtyNitric Oxide Synthase Type IIAutopsyBiologyHypoxemiaNitric oxideYoung Adultchemistry.chemical_compoundAnoxiaInternal medicinemedicineHumansYoung adultChildPreschoolAgedCarotid BodyAdult; Aged; Aging; Anoxia; Carotid Body; Cell Differentiation; Child Preschool; Humans; Nitric Oxide Synthase Type II; Oxygen; Vascular Endothelial Growth Factor A; Young AdultCell DifferentiationHypoxia (medical)Oxygenmedicine.anatomical_structureEndocrinologyHypoxia-inducible factorschemistryImmunohistochemistryCarotid bodymedicine.symptom
researchProduct

The chaperone system in glioblastoma multiforme and derived cell lines: diagnostic and mechanistic implications.

2022

BACKGROUND: Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults. Novel treatments are needed to counteract the molecular mechanisms of GBM growth and drug resistance. The chaperone system (CS) members are typically cytoprotective but some, termed Hsp, can become pathogenic and participate in carcinogenesis, along with the vascular endothelial growth factor (VEGF), and we investigated them in GBM biopsies and derived cell lines. The objectives were to identify diagnostic-prognostic biomarkers and gather information for developing chaperonotherapy. METHODS: Cell lines from GBMs were established, characterized (morphology, growth characteristics, and sp…

AdultVascular Endothelial Growth Factor AGeneral Immunology and MicrobiologySettore BIO/16 - Anatomia UmanaBrain Neoplasmschaperone system (CS) glioblastoma multiforme (GBM) GMB cell lines heat shock protein (Hsp) vascular endothelial growth factor (VEGF)HSP27 Heat-Shock ProteinsHumansHSP70 Heat-Shock ProteinsGlioblastomaGeneral Biochemistry Genetics and Molecular BiologyCell LineFrontiers in bioscience (Landmark edition)
researchProduct

Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival

1999

Since detailed knowledge regarding the pathophysiological properties—which in turn are responsible for differences in contrast enhancement—remain fairly undetermined, it was the aim of this study (i) to examine the association of standard and pharmacokinetic analysis of time-intensity curves in dynamic MRI with histomorphological markers of tumor angiogenesis (microvessel density [MVD]; vascular endothelial growth factor [VEGF]) and (ii) to determine the ultimate value of a histomorphological and a dynamic MRI approach by correlation of those data with disease outcome in patients with primary cancer of the uterine cervix. Pharmacokinetic parameters (amplitude A, exchange rate constantk 21) …

AdultVascular Endothelial Growth Factor APathologymedicine.medical_specialtyTime FactorsBiophysicsUterine Cervical NeoplasmsEndothelial Growth Factorschemistry.chemical_compoundText miningPharmacokineticsBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingSurvival analysisCervical cancerLymphokinesNeovascularization PathologicRadiological and Ultrasound TechnologyVascular Endothelial Growth Factorsbusiness.industryMicrocirculationGold standard (test)Middle Agedmedicine.diseaseMagnetic Resonance ImagingPathophysiologySurvival RateVascular endothelial growth factorchemistryDynamic contrast-enhanced MRIFemaleNuclear medicinebusinessMagnetic Resonance Materials in Physics, Biology and Medicine
researchProduct

Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hypersti…

2013

Objective To ascertain whether vascular endothelial growth factor (VEGF) secretion by luteinized granulosa cells (GCs) is modulated by the dopaminergic system in a dose-dependent fashion and how this is related to the differential efficacy of dopamine receptor 2 (D2)-agonists (D2-ag) in preventing ovarian hyperstimulation syndrome (OHSS). Design The relationship between the dopaminergic system and VEGF secretion in luteinized GCs was evaluated. Archived human ovaries were immunostained to characterize D2 expression. Setting University affiliated infertility center. Patient(s) Premenopausal women and egg donors. Intervention(s) Luteinized GCs were cultured with the D2-ag cabergoline. Human o…

AdultVascular Endothelial Growth Factor Aendocrine systemmedicine.medical_specialtyOvarian hyperstimulation syndromePilot ProjectsLuteal phaseBiologyOvarian Hyperstimulation Syndromechemistry.chemical_compoundCabergolineInternal medicinemedicineHumansSecretionCells CulturedGranulosa CellsReceptors Dopamine D2OvaryDopaminergicObstetrics and GynecologyMiddle Agedmedicine.diseaseVascular endothelial growth factorTreatment OutcomeEndocrinologyReproductive MedicinechemistryDopamine receptorDopamine AgonistsImmunohistochemistryFemalesense organsmedicine.drugFertility and Sterility
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct

Modifications in the production of cytokines and growth factors in drainage fluids following mesh implantation after incisional hernia repair

2005

Abstract Background The aim of this study was to evaluate changes in the production of some cytokines (interleukins [ILs]-6, -10, -1, and -1ra), vascular endothelial growth factor, and beta-fibroblast growth factor after polypropylene mesh implantation. Methods Twenty female patients were divided into 2 groups. In 1 group, hernia repair was performed with conventional sutures (CR), whereas in the other group polypropylene mesh (MR) was used. Growth factors and cytokines production was analyzed in wound drain fluids based on the amount produced during 24 hours. Results IL-1 increased substantially in MR patients on postoperative days 1 and 2. IL1-ra and IL-10 production was always significan…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyincisional herniaIncisional herniamedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayPolypropyleneschemistry.chemical_compoundmedicineHumansHerniaProspective StudiesPostoperative CareLaparotomyPain Postoperativebusiness.industryInterleukinsGrowth factorSuture Techniquesgrowth factorGeneral MedicineMiddle AgedSurgical Meshmedicine.diseaseHernia repairHernia Ventralinterieukinmesh implantationSurgeryVascular endothelial growth factorTreatment OutcomeCytokineSurgical meshchemistryCytokinesFemaleSurgeryInflammation MediatorsVascular endothelial growth factor productionbusinessFollow-Up Studies
researchProduct

Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF r…

2006

No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist(SU5416).However,duetoitstoxicity(thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, use…

AgonistVascular Endothelial Growth Factor Amedicine.medical_specialtyCabergolinemedicine.drug_classAngiogenesisOvarian hyperstimulation syndromeNeovascularization PhysiologicBiologyDopamine agonistCapillary Permeabilitychemistry.chemical_compoundOvarian Hyperstimulation SyndromeEndocrinologyCorpus LuteumInternal medicineCabergolinemedicineAnimalsRNA MessengerErgolinesPhosphorylationRats WistarReceptors Dopamine D2Kinase insert domain receptorReceptor antagonistmedicine.diseaseVascular Endothelial Growth Factor Receptor-2RatsVascular endothelial growth factorDisease Models AnimalEndocrinologychemistryDopamine AgonistsFemalemedicine.drugEndocrinology
researchProduct

Arterial hypertension in cancer: The elephant in the room

2019

The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, var…

Arterial hypertensionVascular Endothelial Growth Factor AAnthracyclines Anti VEGF agents Anti-hypertensive therapy Arterial hypertension Cancer Cardiotoxicitymedicine.medical_specialtyAnti VEGF agentmedicine.medical_treatmentAntineoplastic AgentsBlood PressureAnthracycline030204 cardiovascular system & hematologyAnthracyclines; Anti VEGF agents; Anti-hypertensive therapy; Arterial hypertension; Cancer; Cardiotoxicity; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Humans; Hypertension; Neoplasms; Vascular Endothelial Growth Factor A03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansAnthracyclines030212 general & internal medicineAnti-hypertensive therapyAdverse effectIntensive care medicineAntihypertensive AgentsCancerChemotherapyCardiotoxicitybusiness.industryAnti VEGF agentsCancermedicine.diseaseComorbidityCardiotoxicityDiscontinuationBlood pressureHeart failureHypertensionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Modulation of platelet activation and initial cytokine release by alloplastic bone substitute materials.

2010

Objectives: Platelet-derived cytokines play a crucial role in tissue regeneration. In regenerative dental medicine, bone substitute materials (BSM) are widely used. However, initial interactions of BSM and platelets are still unknown. The aim of this study was to evaluate the potential of platelet activation and subsequent initial cytokine release by different commercial alloplastic BSM. Material and methods: Eight commercial BSM of different origins and chemical compositions (tricalcium phosphate, hydroxyapatite, bioactive glass: SiO2 and mixtures) were incubated with a platelet concentrate (platelet-rich plasma, PRP) of three healthy volunteers at room temperature for 15 min. Platelet cou…

Blood PlateletsCalcium PhosphatesVascular Endothelial Growth Factor APlatelet Aggregationmedicine.medical_treatmentPharmacologyCell Degranulationlaw.inventionlawmedicineHumansPlateletPlatelet activationPlatelet-Derived Growth FactorbiologyChemistryPlatelet CountPlatelet-Rich PlasmaGrowth factorDegranulationFlow CytometryPlatelet ActivationSilicon DioxideP-SelectinCytokineDurapatiteBioactive glassPlatelet-rich plasmaImmunologyBone Substitutesbiology.proteinOral SurgeryPlatelet-derived growth factor receptorClinical oral implants research
researchProduct

Analysis and comparison of autologous platelet-rich plasma preparation systems used in the treatment of enthesopathies: A preliminary study

2021

Background Autologous platelet-rich plasma (PRP) injection is an alternative but widely accepted method for the treatment of degenerative changes in tendon attachments known as enthesopathies. The PRP is considered a safe source for high concentrations of the growth factors involved in the healing process. Despite initial promising outcomes, many recent studies report conflicting results for this treatment. This may be due to differences in the concentrations of platelets and growth factors in PRPs obtained using different methods. Objectives The aim of this study was to compare PRP preparation systems in terms of morphotic components and selected growth factors to find the most appropriate…

Blood PlateletsMaleVascular Endothelial Growth Factor APlatelet-derived growth factormedicine.medical_treatmentPopulationMedicine (miscellaneous)EnthesopathyGeneral Biochemistry Genetics and Molecular Biologyplatelet-derived growth factorTransforming Growth Factor beta1AndrologyLeukocyte Countchemistry.chemical_compoundEpidermal growth factorgrowth factorsInternal MedicinemedicineHumansPharmacology (medical)PlateleteducationGenetics (clinical)Whole bloodeducation.field_of_studyEpidermal Growth FactorPlatelet-Rich Plasmabusiness.industryGrowth factorVascular endothelial growth factorchemistryPlatelet-rich plasmaReviews and References (medical)businessAdvances in Clinical and Experimental Medicine
researchProduct